Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer

Cancer Research

Volumn 60, Issue 7, 2000, Pages 1878-1886

  Browder, Timothy ^a,c   Butterfield, Catherine E ^a   Kräling, Birgit M ^a   Shi, Bin ^a   Marshall, Blair ^a   O'Reilly, Michael S ^a,d   Folkman, Judah ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d HARVARD RADIATION ONCOLOGY PROGRAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; FLUOROURACIL; FUMAGILLOL CHLOROACETYLCARBAMATE; MERCAPTOPURINE; ONDANSETRON; PROTEIN P53;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BREAST CARCINOMA; CANCER CHEMOTHERAPY; CANCER INHIBITION; CAPILLARY ENDOTHELIUM; CATTLE; CONTROLLED STUDY; DRUG EFFICACY; ENDOTHELIUM CELL; EXPERIMENTAL NEOPLASM; HUMAN; HUMAN CELL; LEUKEMIA; LEWIS CARCINOMA; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR VASCULARIZATION;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CORNEA; CYCLOPHOSPHAMIDE; DRUG ADMINISTRATION SCHEDULE; DRUG CARRIERS; DRUG RESISTANCE, MULTIPLE; FEMALE; FLUOROURACIL; GENES, P53; LEUKEMIA L1210; LIPOSOMES; LUNG NEOPLASMS; MALE; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED STRAINS; NEOVASCULARIZATION, PATHOLOGIC; NEOVASCULARIZATION, PHYSIOLOGIC; THIOINOSINE;

EID: 0034032882     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (60)

1. Farber, S., Diamond, L. K., and Mercer, R. D. Temporary remissions in acute leukemia in children produced by folic acid antagonist 4-aminopteroylglutamic acid (aminopterin). N. Engl. J. Med., 238: 787-793, 1948.
2. Bailar, J. C., and Gornink, H. L. Cancer undefeated. N. Engl. J. Med., 336: 1569-1574, 1997.
3. Skipper, H. E., Schabel, F. M., and Wilcox, W. S. Experimental evaluation of potential anticancer agents. XIII. On the criteria and kinetics associated with "curability" of experimental leukemia. Cancer Chemother. Rep., 35: 1-111, 1964.
4. Hill, D. L. A Review of Cyclophosphamide. Springfield, IL: Charles C. Thomas, 1975.
5. Kerbel, R. S. Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents. Bioessays, 13: 31-36, 1991.
6. Boehm, T., Folkman, J., Browder, T., and O'Reilly, M. S. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature (Lond.), 390: 404-407, 1997.
7. Teicher, B. A., Herman, T. S., Holden, S. A., Wang, Y. Y., Pfeffer, M. R., Crawford, J. W., and Frei, E., III. Tumor resistance to alkylating agents conferred by mechanisms operative only in vivo. Science (Washington DC), 247: 1457-1461, 1990.
8. O'Reilly, M. S. et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by Lewis lung carcinoma. Cell, 79: 315-328, 1994.
9. Venditti, J. M., Humphreys, S. R., and Goldin, A. Investigation of the activity of cytoxan against leukemia L1210 in mice. Cancer Res., 19: 986-995, 1959.
10. Ingber, D. et al. Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth. Nature (Lond.), 348: 555-557, 1990.
11. Olver, I. N., Roos, I. G., Thomas, K., and Hillcoat, B. L. Development of a murine gastric distension model for testing the emetic potential of new drugs and efficacy of antiemetics. Chem. Biol. Interact., 69: 353-357, 1989.
12. Folkman, J., Haudenschild, C. C., and Zetter, B. R. Long-term culture of capillary endothelial cells. Proc. Natl. Acad. Sci. USA, 76: 5217-5221, 1979.
13. Moses, M. A., Sudhalter, J., and Langer, R. Identification of an inhibitor of neovascularization from cartilage. Science (Washington DC), 248: 1408-1410, 1990.
14. Goldin, A. et al. Current results of the screening program at the Division of Cancer Treatment, National Cancer Institute. Eur. J. Cancer, 17: 129-142, 1981.
15. Skipper, H. E., and Schmidt, L. H. A manual of quantitative drug evaluation in experimental tumor systems. Cancer Chemother. Rep., 17: 1-178, 1962.
16. Humphreys, S. R., and Karrer, K. Relationship of dose schedules to the effectiveness of adjuvant chemotherapy. Cancer Chemother. Rep., 54: 379-392, 1970.
17. Skipper, H. E. What Phenomena Affect the Shapes and Slopes of Dose-Response Curves. Time-Action Curves, Tumor-Mass-Behavior Curves, Remission-Duration Curves, and Host-Survival Curves? pp. 97-115. Birmingham, AL: Southern Research Institute, 1989.
18. Teicher, B. A. et al. Potentiation of cytotoxic cancer therapies by TNP-470 alone and with other anti-angiogenic agents. Int. J. Cancer, 57: 920-925, 1994.
19. D'Incalci, M. et al. Decreased half-life of cyclophosphamide in patients under continual treatment. Eur. J. Cancer, 19: 7-10, 1979.
20. Kachel, D. L., and Martin, W. J., II. Cyclophosphamide-induced lung toxicity: mechanism of endothelial cell injury. J. Pharmacol. Exp. Ther., 268: 42-46, 1994.
21. Mellett, L. B. Chemistry and metabolism of cyclophosphamide. In: M. E. Vancil (ed.), Immunosuppressive Properties of Cyclophosphamide, pp. 6-34. Evansville, IN: Mead Johnson & Company, 1971.
22. Sladek, N. E. Metabolism and pharmacokinetic behavior of cyclophosphamide and related oxazophosphorines. In: G. Powis (ed.). Anticancer Drugs: Reactive Metabolism and Drug Interactions, pp. 79-156. Oxford, United Kingdom: Pergamon Press Ltd., 1994.
23. Donehower, L. A. et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature (Lond.), 356: 215-221, 1992.
24. Kastan, M. B. The p53 tumor suppressor gene: a multifaceted cancer threat. Adv. Oncol., 12: 3-7, 1996.
25. Lowe, S. W., Ruley, H. E., Jacks, T., and Housman, D. E. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell, 74: 957-967, 1993.
26. Hawkins, D. S., Demers, G. W., and Galloway, D. A. Inactivation of p53 enhances sensitivity to multiple chemotherapeutic agents. Cancer Res., 56: 892-898, 1996.
27. Brem, H., and Folkman, J. Analysis of experimental antiangiogenic therapy. J. Pediatr. Surg., 28: 445-451, 1993.
28. Folkman, J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med., 285: 1182-1186, 1971.
29. Baguley, B. C., Holdaway, K. M., Thomsen, L. L., Zhuang, L., and Zwi, L. J. Inhibition of growth of colon 38 adenocarcinoma by vinblastine and colchicine: evidence for a vascular mechanism. Eur. J. Cancer, 27: 482-487, 1991.
30. Denekamp, J. Endothelial cell proliferation as a novel approach to targeting tumor therapy. Br. J. Cancer, 45: 136-139, 1982.
31. Denekamp, J. Angiogenesis, neovascular proliferation and vascular pathophysiology as targets for cancer therapy. Br. J. Radiol., 66: 181-196, 1993.
32. Venditti, J. M., Goldin, A., and Kline, I. The influence of treatment schedule on the chemotherapy of advanced leukemia L1210 in mice. Cancer Chemother. Rep., 6: 55-57, 1960.
33. Lane, M. Animal investigations with cyclophosphamide (NSC-26271): a brief summary. Cancer Chemother. Rep., 51: 359-362,1967.
34. Braunschweiger, P., and Schiffer, L. M. Cell kinetic-directed sequential chemotherapy with cyclophosphamide and Adriamycin in T1699 mammary tumors. Cancer Res., 40: 737-743, 1980.
35. Mattern, J., Wauss, K., and Vol, M. Optimum time sequence for the administration of cyclophosphamide and other drugs in vivo. Anticancer Res., 5: 173-178, 1985.
36. Nuyts, R. M. M. A., Pels, E., and Greve, E. L. The effects of 5-fluorouracil and mitomycin C on the corneal endothelium. Curr. Eye Res., 11: 565-570, 1992.
37. Hoorn, C., Wagner, J. G., Petry, T. W., and Roth, R. A. Toxicity of mitomycin C toward cultured pulmonary artery endothelium. Toxicol. Appl. Pharmacol., 130: 87-94, 1995.
38. Steiner, R. Angiostatic activity of anticancer agents in the chick embryo chorioallantoic membrane (CHE-CAM) assay In: R. Steiner, P. B. W., and R. Langer (eds.), Angiogenesis. Key Principles - Science - Technology - Medicine, pp. 449-454. Basel, Switzerland: Birkhauser Verlag, 1992.
39. Vacca, A., et al. Anliangiogenesis is produced by nontoxic doses of vinblastine. Blood, 94: 4143-4155, 1999.
40. Belotti, D., et al. The microtubule-affecting drug paclitaxel has anliangiogenic activity. Clin. Cancer Res., 2: 1843-1849, 1996.
41. Klauber, N., Parangi, S., Hamel, E., Flynn, E., and D'Amalo, R. J. Inhibition of angiogenesis in vivo by the microtubule inhibitors 2-methoxyestradiol and Taxol. Cancer Res., 57: 81-86, 1997.
42. Lau, D. H., Xue, L., Young, L. J., Burke, P. A., and Cheung, A. T. Paclitaxel (Taxol): an inhibitor of angiogenesis in a highly vascularized transgenic breast cancer. Cancer Biother. Radiopharm., 14: 31-37, 1999.
43. Presta, M., et al. Purine analogue 6-methylmercaptopurine riboside inhibits early and late stages of the angiogenesis process. Cancer Res., 59: 2417-2424, 1999.
44. Yonekura, K., et al. UFT and its metabolites inhibit the angiogenesis induced by murine renal cell carcinoma, as determined by a dorsal air sac assay in mice. Clin. Cancer Res., 5: 2185-2191, 1999.
45. O'Leary, J. J., et al. Antiangiogenic effects of camptothecin analogues 9-amino-20(S)-camptothecin, topotecan, and CPT-11 studied in the mouse cornea model. Clin. Cancer Res., 5: 181-187, 1999.
46. Iyer, S., et al. Induction of apoptosis in proliferating human endothelial cells by the tumor-specific antiangiogenesis agent combretastatin A-4. Cancer Res., 58: 4510-4514, 1998.
47. Chaplin, D. J., Pettit, G. R., and Hill, S. A. Anti-vascular approaches to solid tumour therapy: evaluation of combretastatin A4 phosphate. Anticancer Res., 19: 189-196, 1999.
48. Hirai, S., et al. Fibroblast growth factor-dependent metabolism of hypoxanthine via the salvage pathway for purine synthesis in porcine aortic endothelial cells. Biochem. Pharmacol., 45: 1695-1701, 1993.
49. Papahadjopoulos, D., et al. Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. Proc. Natl. Acad. Sci. USA, 88: 11460-11464, 1991.
50. Williams, S. S., et al. Arrest of human lung tumor xenograft growth in severe combined immunodeficient mice using doxorubicin encapsulated in sterically stabilized liposomes. Cancer Res., 53: 3964-3967, 1993.
51. Vaage, J., Donovan, D., Loftus, T., Uster, P., and Working, P. Prophylaxis and therapy of mouse mammary carcinomas with doxorubicin and vincristine encapsulated in sterically stabilized liposomes. Eur. J. Cancer, 31A: 367-372, 1995.
52. Meta-Analysis Group in Cancer. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J. Clin. Oncol., 16: 301-308, 1998.
53. Gabra, H., Cameron, D. A., Lee, L. E., Mackay, J., and Leonard, R. C. Weekly doxorubicin and continuous infusional 5-fluorouracil for advanced breast cancer. Br. J. Cancer, 74: 2008-2012, 1996.
54. Hansen, R. M., et al. Phase III study of bolus versus infusion fluorouracil with or without cisplatin in advanced colorectal cancer. J. Natl. Cancer Inst., 88: 668-674, 1996.
55. Seidman, A. D., Hudis, C. A., Albanel, J., Tong, W., Tepler, I., Currie, V., Moynahan, M. E., Theodoulou, M., Gollub, M. Baselga, J., and Norton, L. Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast career. J. Clin. Oncol., 16: 3353-3361, 1998.
56. Abu-Rustum, N. R., et al. Salvage weekly paclitaxel in recurrent ovarian cancer. Semin. Oncol., 24 (Suppl. 15): 62-67, 1997.
57. Loffler, T. M., Freund, W., Lipke, J., and Hausamen, T. U. Schedule- and dose-intensified paclitaxel as weekly 1-hour infusion in pretreated solid tumors: results of a Phase I/II trial. Semin. Oncol., 23 (Suppl. 16): 32-34, 1996.
58. Kakolyris, S., et al. Treatment of non-small-cell lung cancer with prolonged oral etoposide. Am. J. Clin. Oncol., 21: 505-508, 1998.
59. Chamberlain, M. C. Recurrent supratentorial malignant gliomas in children, long-term salvage therapy with oral etoposide. Arch. Neurol., 54: 554-558, 1997.
60. Neskovic-Konstantinovic, Z. B., Bosnjak, S. M., Radulovic, S. S., and Mitrovic, L. B. Daily oral etoposide in metastatic breast cancer. Anti-Cancer Drugs, 7: 543-547. 1996.